RT期刊文章SR电子T1基线身体活动概要CREST-2试验参与者(p1.3 - 056)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p1.3补充92 - 056签证官是15 A1 Seem首页ant查图尔维迪A1谭雅图兰A1尼尔·戈登A1珍妮弗Voeks A1 Marc Chimowitz A1弗吉尼亚A1乔治·霍华德A1凯文·巴雷特A1罗伯特·布朗A1罗纳德•拉扎尔A1韦斯利摩尔A1克劳迪娅Moy A1加里Roubin A1巴特Demaerschalk A1马尔科姆·福斯特A1劳伦斯韦氏A1 Brajesh Lal A1詹姆斯Meschia A1托马斯王硕年2019 UL //www.ez-admanager.com/content/92/15_supplement/p1.3 - 056. -文摘AB目的:基于试验数据的颅内狭窄患者,我们旨在评估颈动脉狭窄< 40%的受试者的假设会有最佳的身体活动水平。我们也评估关键子组确定的物理活动模式。背景:身体活动的重要性在预防主要血管事件已经在过去的十年中受到更多的关注。由于包含INTERVENT生活方式的修改程序,CREST2试验提供了一个独特的机会来研究体育活动资料严重的无症状患者颅外颈动脉狭窄。设计/方法:我们分析了1087年CREST2参与者与基线数据在体力活动。Physician-based评估和咨询运动(速度)得分记录了每个病人和一分为二的“目标”(4 - 8分)或“目标”(< 4分)。速度得分< 4显示一个主题不参与有规律的锻炼。整个试验结果进行了分析。x平方分布检验和t进行小组评价的差异。结果:研究人口的平均年龄为69.5±7.8年(60%的男性)。基线的平均速度得分是4.0(平均3.8±2.1;差2—6)。表显示患者的基线特征意味着速度得分。 Being male, not having diabetes mellitus, having a body mass index <30kg/m2, being a non-smoker, and not having a history of peripheral arterial disease were associated with significantly higher mean PACE scores (P<0.01).Conclusions: We have defined several patient groups with asymptomatic carotid stenosis that have suboptimal physical activity. These results provide opportunities for targeted efforts to improve primary stroke prevention. These baseline data will also allow investigators to determine if trial involvement and the INTERVENT program leads to improvement in the level of physical activity.Disclosure: Dr. Chaturvedi has received personal compensation in an editorial capacity for NEJM Journal Watch Neurology. Dr. Chaturvedi has received research support from Boehringer Ingelheim. Dr. Turan has nothing to disclose. Dr. Gordon has nothing to disclose. Dr. Voeks has nothing to disclose. Dr. Chimowitz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bristol Myers Squibb. Dr. Howard has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Lazar has nothing to disclose. Dr. Moore has nothing to disclose. Dr. Moy has nothing to disclose. Dr. Roubin has nothing to disclose. Dr. Demaerschalk has nothing to disclose. Dr. Foster has nothing to disclose. Dr. Wechsler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Athersys. Dr. Lal has nothing to disclose. Dr. Meschia has nothing to disclose. Dr. Brott has nothing to disclose.

map